Crescent Biopharma, Inc. (CBIO) stock forecast and price target
Price $14.15 · data as of November 13, 2026
12-month price target
Average target$32.33
Upside / downside+128.5%
Analysts6
ConsensusStrong buy
Low $28.00Average $32.33High $40.00
Gold marker: average target · white marker: today’s price ($14.15)
Analyst ratings
Strong buy 1Buy 7Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-2.76 | +78.4% | $3M |
| Next fiscal year ends December 31, 2027 | $-3.07 | −11.1% | $4M |
| Next quarter ends December 31, 2026 | $-0.74 | +85.0% | $833330 |
| Quarter after ends March 31, 2027 | $-0.65 | +7.1% | $0 |
Consensus of the analysts covering Crescent Biopharma, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.
Frequently asked questions
What is the Crescent Biopharma stock price target?
The average 12-month target from 6 analysts is $32.33, 128.5% above the current price of $14.15 Targets range from $28.00 to $40.00.
Is Crescent Biopharma a buy according to analysts?
The consensus rating is “Strong buy” (1 strong buy, 7 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Crescent Biopharma expected to earn?
Analysts expect EPS of $-2.76 for the fiscal year ending December 31, 2026 and $-3.07 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.